Crossmark

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?

Crossref DOI link: https://doi.org/10.1016/j.aohep.2023.101141

Published Print: 2023-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Brustia, Raffaele http://orcid.org/0000-0001-6426-9533
Bouattour, Mohamed

Allaire, Manon

Lequoy, Marie

Hollande, Clémence http://orcid.org/0000-0002-2287-0635
Regnault, Hélène http://orcid.org/0000-0001-6810-9406
Blaise, Lorraine

Ganne-Carrié, Nathalie

Vilgrain, Valérie

Larrey, Edouard

Lim, Chetana

Scatton, Olivier

Mouhadi, Sanaa El

Ozenne, Violaine

Paye, François

Balladur, Pierre

Dohan, Anthony

Massault, Pierre-Philippe

Pol, Stanislas

Dioguardi Burgio, Marco

Sepulveda, Ailton

Cauchy, Francois

Luciani, Alain

Sommacale, Daniele

Leroy, Vincent

Calderaro, Julien

Roudot-Thoraval, Francoise

Nault, Jean-Charles

Amaddeo, Giuliana
License Information

Text and Data Mining valid from 2023-11-01

Text and Data Mining valid from 2023-11-01

Version of Record valid from 2023-07-14
More Information

This article is maintained by: Elsevier

Article Title: Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?

Journal Title: Annals of Hepatology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.aohep.2023.101141

Content Type: article

Copyright: © 2023 Published by Elsevier España, S.L.U. on behalf of Fundación Clínica Médica Sur, A.C.